Risperidone Augmentation of Selective Serotonin Reuptake Inhibitors in Major Depression
Abstract
Background At low doses, risperidone acts as a 5-HT2 antagonist. Preclinical data suggest 5-HT2 antagonists may enhance the action of serotonin. This report examines the clinical use of risperidone to augment selective serotonin reuptake inhibitor (SSRI) anti-depressants in patients who have not responded to SSRI therapy. Method In 8 patients with major depressive disorder without psychotic features (DSM-IV) who had not responded to an SSRI, risperidone was added to the ongoing SSRI treatment. Hamilton Rating Scale for Depression scores were obtained before and after the addition of risperidone. Results These 8 patients remitted within 1 week of the addition of risperidone. Risperidone also appeared to have beneficial effects on sleep disturbance and sexual dysfunction. Conclusion Risperidone may be a useful adjunct to SSRIs in the treatment of depression.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The addition of risperidone has been found to reduce sleep disturbance in resistant depression.
“The addition of the novel antipsychotic risperidone has been found to reduce sleep disturbance in resistant depression (Ostroff and Nelson, 1999), but there is much more evidence for hypnotics.”
From Antidepressants and their effect on sleep (2005) · cites this paper as Ostroff and Nelson, 1999
Cited by
Sorted by citations
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970 · see citing works
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739 · see citing works
Dopamine system dysregulation in major depressive disorders
Belujon, P., & Grace, A. A. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx056 · Cited by 754 · see citing works
Nelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552 · see citing works
Self-citationKodama, M., Fujioka, T., & Duman, R. S. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.07.008 · Cited by 387 · see citing works
Sexual Dysfunction, Depression, and the Impact of Antidepressants
Kennedy, S. H., & Rizvi, S. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31819c76e9 · Cited by 338 · see citing works
Antidepressants and their effect on sleep
Mayers, A. G., & Baldwin, D. S. (2005) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.726 · Cited by 323 · see citing works
Peterson, M. J., & Benca, R. M. (2006) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2006.09.003 · Cited by 164 · see citing works
McIntyre, A., Gendron, A., & McIntyre, A. (2007) · Depression and Anxiety · doi:10.1002/da.20275 · Cited by 145 · see citing works
Risperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial
Mahmoud, R. A., Pandina, G. J., Turkoz, I., Kosik-Gonzalez, C., Canuso, C. M., Kujawa, M. J., & Gharabawi-Garibaldi, G. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00003 · Cited by 140 · see citing works
Carvalho, A. F., Cavalcante, J. L., Castelo, M. S., & Lima, M. C. O. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00846.x · Cited by 110 · see citing works
Keitner, G. I., Garlow, S. J., Ryan, C. E., Ninan, P. T., Solomon, D. A., Nemeroff, C. B., & Keller, M. B. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.05.003 · Cited by 108 · see citing works
Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76 · see citing works
Boothman, L. J., Mitchell, S. N., & Sharp, T. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.11.020 · Cited by 67 · see citing works
- Authors
- Ostroff, R. B., & Nelson, J. C.
- ORCID
- Ostroff, Robert B.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 1999-04-15
- Volume
- 60
- Issue
- 4
- Pages
- 256-259
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2005066505
- Cited by
- 248
- References
- 0
- Citations by year
- 2025: 2 · 2024: 1 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 5 · 2018: 3 · 2017: 7 · 2016: 5 · 2015: 7 · 2014: 6 · 2013: 10 · 2012: 8
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- risperidone, selective serotonin reuptake inhibitors, major depressive disorder, antidepressant augmentation, 5-HT2 receptor antagonism, treatment-resistant depression, adjunctive therapy, sleep disorders, sexual dysfunction
- MeSH terms
- Adult, Aged, Ambulatory Care, Depressive Disorder, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Fluoxetine, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Serotonin Antagonists, Antipsychotic Agents, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Paroxetine, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
